液体血浆诱导头颈部癌细胞无炎症反应的坏死下垂。

IF 2.2 Q3 ONCOLOGY
World Journal of Oncology Pub Date : 2025-09-17 eCollection Date: 2025-10-01 DOI:10.14740/wjon2579
Jae Hoon Choi, Sungryeal Kim, Yun Sang Lee, Young Suk You, Jeon Yeob Jang, Yoo Seob Shin, Chul-Ho Kim
{"title":"液体血浆诱导头颈部癌细胞无炎症反应的坏死下垂。","authors":"Jae Hoon Choi, Sungryeal Kim, Yun Sang Lee, Young Suk You, Jeon Yeob Jang, Yoo Seob Shin, Chul-Ho Kim","doi":"10.14740/wjon2579","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Several types of regulated cell deaths are known, including apoptosis, necroptosis, autophagy, ferroptosis, and pyroptosis. Among these types of cell deaths, apoptosis is induced by many cancer therapeutic agents. In the case of resistance, however, induction of other regulated cell death, such as necroptosis, are required. Liquid plasma, which is prepared by treatment of non-thermal plasma to solution, induces various types of regulated cell death via reactive oxygen and nitrogen species.</p><p><strong>Methods: </strong>Liquid plasma was generated by N<sub>2</sub>/Ar plasma treatment in culture medium (minimum essential medium (MEM), Dulbecco's modified Eagle medium (DMEM), or Roswell Park Memorial Institute (RPMI)-1640) for 120 s per milliliter of medium (2 cm). Cell viability was determined using Cell Counting Kit-8 (CCK8), and apoptosis was determined by terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL) assay. Tumor necrosis factor alpha (TNF-α), cycloheximide (CHX), and zVAD-fmk were used to induce necroptosis in head and neck squamous cell carcinoma (HNSCC) cells, and necroptosis inhibitors, such as necrostatin-1 (Nec-1, 50 µM), GSK872 (10 µM), and necrosulfonamide (NSA, 2 µM) were used to inhibit necroptosis. Statistical comparisons between groups were carried out using the Student's <i>t</i>-test.</p><p><strong>Results: </strong>Here, we determined the type of cell death induced by liquid plasma in head and neck cancer (HNC) cells. Our results show that liquid plasma caused necroptosis in HNC cells, and peroxynitrite in the liquid plasma might be involved in the cell death. The expression of inflammation-related molecules, including nuclear factor kappa B (NF-κB), interleukin (IL)-6, and mitochondrial antiviral signaling proteins, were detected in HNC cells, and treatment of HNC cells with liquid plasma decreased their expression.</p><p><strong>Conclusions: </strong>These results suggest that liquid plasma could be used to treat HNC by inducing necroptosis without inflammatory responses. In this study, we demonstrated that liquid plasma treatment may kill HNC cells without causing necroptosis-induced inflammation and inflammation-mediated diseases.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 5","pages":"457-470"},"PeriodicalIF":2.2000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479077/pdf/","citationCount":"0","resultStr":"{\"title\":\"Liquid Plasma Induces Necroptosis Without Inflammatory Responses in Head and Neck Cancer Cells.\",\"authors\":\"Jae Hoon Choi, Sungryeal Kim, Yun Sang Lee, Young Suk You, Jeon Yeob Jang, Yoo Seob Shin, Chul-Ho Kim\",\"doi\":\"10.14740/wjon2579\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Several types of regulated cell deaths are known, including apoptosis, necroptosis, autophagy, ferroptosis, and pyroptosis. Among these types of cell deaths, apoptosis is induced by many cancer therapeutic agents. In the case of resistance, however, induction of other regulated cell death, such as necroptosis, are required. Liquid plasma, which is prepared by treatment of non-thermal plasma to solution, induces various types of regulated cell death via reactive oxygen and nitrogen species.</p><p><strong>Methods: </strong>Liquid plasma was generated by N<sub>2</sub>/Ar plasma treatment in culture medium (minimum essential medium (MEM), Dulbecco's modified Eagle medium (DMEM), or Roswell Park Memorial Institute (RPMI)-1640) for 120 s per milliliter of medium (2 cm). Cell viability was determined using Cell Counting Kit-8 (CCK8), and apoptosis was determined by terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL) assay. Tumor necrosis factor alpha (TNF-α), cycloheximide (CHX), and zVAD-fmk were used to induce necroptosis in head and neck squamous cell carcinoma (HNSCC) cells, and necroptosis inhibitors, such as necrostatin-1 (Nec-1, 50 µM), GSK872 (10 µM), and necrosulfonamide (NSA, 2 µM) were used to inhibit necroptosis. Statistical comparisons between groups were carried out using the Student's <i>t</i>-test.</p><p><strong>Results: </strong>Here, we determined the type of cell death induced by liquid plasma in head and neck cancer (HNC) cells. Our results show that liquid plasma caused necroptosis in HNC cells, and peroxynitrite in the liquid plasma might be involved in the cell death. The expression of inflammation-related molecules, including nuclear factor kappa B (NF-κB), interleukin (IL)-6, and mitochondrial antiviral signaling proteins, were detected in HNC cells, and treatment of HNC cells with liquid plasma decreased their expression.</p><p><strong>Conclusions: </strong>These results suggest that liquid plasma could be used to treat HNC by inducing necroptosis without inflammatory responses. In this study, we demonstrated that liquid plasma treatment may kill HNC cells without causing necroptosis-induced inflammation and inflammation-mediated diseases.</p>\",\"PeriodicalId\":46797,\"journal\":{\"name\":\"World Journal of Oncology\",\"volume\":\"16 5\",\"pages\":\"457-470\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479077/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14740/wjon2579\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/wjon2579","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:几种类型的调节细胞死亡是已知的,包括凋亡、坏死性死亡、自噬、铁性死亡和焦亡。在这些类型的细胞死亡中,凋亡是由许多癌症治疗剂诱导的。然而,在耐药性的情况下,需要诱导其他受调节的细胞死亡,如坏死性死亡。液态等离子体是由非热等离子体处理成溶液制备的,通过活性氧和活性氮诱导各种类型的调节细胞死亡。方法:采用N2/Ar等离子体在培养基(最低基本培养基(MEM)、Dulbecco's modified Eagle培养基(DMEM)或Roswell Park Memorial Institute (RPMI)-1640)中处理120 s / ml培养基(2 cm)产生液体血浆。采用细胞计数试剂盒-8 (CCK8)检测细胞活力,采用末端脱氧核苷酸转移酶三磷酸脱氧尿苷(dUTP)缺口末端标记法(TUNEL)检测细胞凋亡。采用肿瘤坏死因子α (TNF-α)、环己亚胺(CHX)和zVAD-fmk诱导头颈部鳞状细胞癌(HNSCC)细胞坏死,采用坏死抑制剂necrostatin-1 (Nec-1, 50µM)、GSK872(10µM)、necrosulfonamide (NSA, 2µM)抑制坏死。组间比较采用学生t检验。结果:本实验确定了液体血浆诱导头颈癌(HNC)细胞死亡的类型。我们的研究结果表明,液体血浆引起HNC细胞坏死,液体血浆中的过氧亚硝酸盐可能参与了细胞死亡。HNC细胞中检测到核因子κB (NF-κB)、白细胞介素(IL)-6、线粒体抗病毒信号蛋白等炎症相关分子的表达,血浆液处理HNC细胞可降低其表达。结论:液体血浆可通过诱导坏死上睑下垂而无炎症反应治疗HNC。在这项研究中,我们证明了液体血浆治疗可以杀死HNC细胞,而不会引起坏死诱导的炎症和炎症介导的疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Liquid Plasma Induces Necroptosis Without Inflammatory Responses in Head and Neck Cancer Cells.

Background: Several types of regulated cell deaths are known, including apoptosis, necroptosis, autophagy, ferroptosis, and pyroptosis. Among these types of cell deaths, apoptosis is induced by many cancer therapeutic agents. In the case of resistance, however, induction of other regulated cell death, such as necroptosis, are required. Liquid plasma, which is prepared by treatment of non-thermal plasma to solution, induces various types of regulated cell death via reactive oxygen and nitrogen species.

Methods: Liquid plasma was generated by N2/Ar plasma treatment in culture medium (minimum essential medium (MEM), Dulbecco's modified Eagle medium (DMEM), or Roswell Park Memorial Institute (RPMI)-1640) for 120 s per milliliter of medium (2 cm). Cell viability was determined using Cell Counting Kit-8 (CCK8), and apoptosis was determined by terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL) assay. Tumor necrosis factor alpha (TNF-α), cycloheximide (CHX), and zVAD-fmk were used to induce necroptosis in head and neck squamous cell carcinoma (HNSCC) cells, and necroptosis inhibitors, such as necrostatin-1 (Nec-1, 50 µM), GSK872 (10 µM), and necrosulfonamide (NSA, 2 µM) were used to inhibit necroptosis. Statistical comparisons between groups were carried out using the Student's t-test.

Results: Here, we determined the type of cell death induced by liquid plasma in head and neck cancer (HNC) cells. Our results show that liquid plasma caused necroptosis in HNC cells, and peroxynitrite in the liquid plasma might be involved in the cell death. The expression of inflammation-related molecules, including nuclear factor kappa B (NF-κB), interleukin (IL)-6, and mitochondrial antiviral signaling proteins, were detected in HNC cells, and treatment of HNC cells with liquid plasma decreased their expression.

Conclusions: These results suggest that liquid plasma could be used to treat HNC by inducing necroptosis without inflammatory responses. In this study, we demonstrated that liquid plasma treatment may kill HNC cells without causing necroptosis-induced inflammation and inflammation-mediated diseases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.10
自引率
15.40%
发文量
37
期刊介绍: World Journal of Oncology, bimonthly, publishes original contributions describing basic research and clinical investigation of cancer, on the cellular, molecular, prevention, diagnosis, therapy and prognosis aspects. The submissions can be basic research or clinical investigation oriented. This journal welcomes those submissions focused on the clinical trials of new treatment modalities for cancer, and those submissions focused on molecular or cellular research of the oncology pathogenesis. Case reports submitted for consideration of publication should explore either a novel genomic event/description or a new safety signal from an oncolytic agent. The areas of interested manuscripts are these disciplines: tumor immunology and immunotherapy; cancer molecular pharmacology and chemotherapy; drug sensitivity and resistance; cancer epidemiology; clinical trials; cancer pathology; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; gene therapy; cancer endocrinology; cancer metastasis; prevention and diagnosis of cancer; other cancer related subjects. The types of manuscripts accepted are original article, review, editorial, short communication, case report, letter to the editor, book review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信